Arkadios Wealth Advisors Purchases 751 Shares of Sanofi (NASDAQ:SNY)

Arkadios Wealth Advisors boosted its holdings in shares of Sanofi (NASDAQ:SNY) by 19.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 4,709 shares of the company’s stock after acquiring an additional 751 shares during the quarter. Arkadios Wealth Advisors’ holdings in Sanofi were worth $227,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in SNY. Dimensional Fund Advisors LP lifted its holdings in shares of Sanofi by 0.4% during the second quarter. Dimensional Fund Advisors LP now owns 318,760 shares of the company’s stock worth $15,466,000 after buying an additional 1,238 shares during the last quarter. AE Wealth Management LLC increased its position in Sanofi by 27.9% during the second quarter. AE Wealth Management LLC now owns 17,308 shares of the company’s stock worth $840,000 after acquiring an additional 3,772 shares during the period. Insigneo Advisory Services LLC raised its stake in Sanofi by 3.3% during the 2nd quarter. Insigneo Advisory Services LLC now owns 7,212 shares of the company’s stock valued at $371,000 after purchasing an additional 228 shares during the last quarter. Point72 Europe London LLP acquired a new stake in Sanofi in the 2nd quarter worth $1,308,000. Finally, Armistice Capital LLC increased its holdings in shares of Sanofi by 15.6% during the 2nd quarter. Armistice Capital LLC now owns 1,500,000 shares of the company’s stock worth $72,780,000 after purchasing an additional 202,000 shares during the period. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th.

Sanofi Stock Up 0.9 %

Shares of NASDAQ:SNY opened at $51.98 on Friday. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97. The firm has a market cap of $131.92 billion, a P/E ratio of 26.52, a P/E/G ratio of 1.19 and a beta of 0.57. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The company’s 50-day moving average price is $48.61 and its two-hundred day moving average price is $52.16.

Sanofi (NASDAQ:SNY) last released its earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. The company had revenue of $13.44 billion during the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The firm’s quarterly revenue was up 12.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.55 earnings per share. As a group, research analysts forecast that Sanofi will post 3.82 EPS for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.